Special Issue

Calcium Channels as Therapeutic Targets

Message from the Guest Editors

Ion channels are key modulators of intracellular levels of Ca2+, which, in turn, is a vital physiological 'second messenger'. Whether modulated through voltage changes, endogenous ligands/protein partners, and/or changes to Ca2+ levels, different Ca2+ channel families represent key molecular targets in a range of pathophysiologies that carry a heavy health, well-being, and economic burden. Thus, Ca2+ channels are major targets in diseases, including pain, epilepsy, neurodegenerative disorders, and neuropsychiatric disorders. This Special Issue will shed light on new pharmacological agents that modulate different classes of Ca2+ channels, including voltage-gated and transient receptor potential channels and/or the auxiliary subunits that make up the protein complex. We welcome submissions from diverse fields of studies, including, but not limited to, the development of small molecular entities and biological drugs, the development of toxins from the plant and animal kingdoms, the exploitation of knowledge of Ca2+ channel structure and function, and genetic studies of channelopathies and disease association.

Guest Editors

Prof. Dr. Gary J. Stephens
Prof. Dr. David Adams
Dr. Hussein N. Rubaiy

Deadline for manuscript submissions

closed (25 July 2025)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/196723

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI